Caplin Point Laboratories profit and loss

Latest FY26
Revenue
₹2,187cr+12.9% on FY25
EBITDA
₹761cr+17.6% on FY25
Net profit
₹650cr+20.1% on FY25
EPS
₹84.36+19.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
2,2872,1871,9371,6941,467
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
12611696.466.956.0
2,4132,3032,0341,7611,523
Expenses
391357248240223
655572576559519
−130−63.7−53.3−74.6−78.9
204199178144137
0.90.90.60.80.8
78.172.866.053.445.0
371362342275225
1,5701,5001,3571,1971,071
797761647551441
718688581498396
Profit
844803677564451
0.00.00.00.30.1
844803677564451
15914612510282.3
6.16.810.41.5−7.9
16515313610374.4
−0.00.0−0.00.00.0
678650541461377
678650541461377
13914227.111.542.8
817791568473420
665641563457376
12.78.54.84.30.7
Per share
₹87.53₹84.36₹70.57₹60.19₹49.62
₹87.28₹84.11₹70.25₹59.90₹49.18
Revenue detail — as filed
—−0.00.00.00.0
Other comprehensive income — detail
13914227.1——
—0.20.1−0.00.4
0.30.00.0——
———−0.00.1
13914127.011.542.4
805783—469419
12.78.5—4.30.7
Per share — as-filed variants
₹87.53₹84.36₹70.57₹60.19₹49.62
₹87.28₹84.11₹70.25₹59.90₹49.18
Derived — gross profit (revenue − materials − purchases − Δ inventories)
1,3721,3221,167970804
60.0%60.4%60.2%57.3%54.8%
Adjusted (ex-exceptional items) — derived
844803677564451
0.00.00.00.30.1
678650541461377
₹87.53₹84.36₹70.57₹60.16₹49.61
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAPLIPOINT₹2,376.10

Caplin Point Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹18,058 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,466.71,694.11,937.52,187.22,287.3
Other Income56.066.996.4115.5126.0
Total Income1,522.71,761.02,033.92,302.72,413.3
Expenses
+ Cost of Materials Consumed223.0239.8248.5357.2390.8
+ Purchases of Stock-in-Trade519.0558.9575.7572.2655.1
+ Changes in Inventories-78.9-74.6-53.3-63.7-130.2
+ Employee Benefit Expense137.0143.6177.7199.2203.8
+ Finance Costs0.80.80.60.90.9
+ Depreciation & Amortisation45.053.466.072.878.1
+ Other Expenses225.5274.9342.0361.5371.4
Total Expenses1,071.41,196.91,357.11,500.01,569.7
EBITDA441.1551.4646.9760.9796.6
EBIT396.1498.0581.0688.1718.5
Profit
PBT before Exceptional Items451.3564.2676.8802.8843.6
+ Exceptional Items0.10.30.00.00.0
Pretax Income451.4564.4676.8802.8843.6
+ Current Tax82.3101.6125.3146.3159.4
+ Deferred Tax-7.91.510.46.86.1
Tax Expense74.4103.0135.7153.1165.5
+ Share of Associates & JVs0.00.0-0.00.0-0.0
Net Income377.0461.4541.1649.7678.1
+ Net Income — Continuing Ops377.0461.4541.1649.7678.1
+ Other Comprehensive Income42.811.527.1141.6139.4
Total Comprehensive Income419.7472.9568.2791.4817.5
Net Income to Common376.3457.1563.4641.2665.4
Minority Interest0.74.34.88.512.7
Per Share
Basic EPS49.6260.1970.5784.3687.53
Diluted EPS49.1859.9070.2584.1187.28
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs0.00.00.0-0.0—
Other Comprehensive Income — detail
+ Other Comprehensive Income——27.1141.6139.4
+ Items NOT to be Reclassified to P&L0.4-0.00.10.2—
+ Tax on Items NOT to be Reclassified——0.00.00.3
+ Tax on Items NOT to be Reclassified — alt tag0.1-0.0———
+ Items to be Reclassified to P&L42.411.527.0141.4139.2
Comprehensive Income — Owners of Parent419.0468.5—782.9804.8
Comprehensive Income — Non-controlling Interests0.74.3—8.512.7
Per Share — as-filed variants
Basic EPS — Continuing Operations49.6260.1970.5784.3687.53
Diluted EPS — Continuing Operations49.1859.9070.2584.1187.28
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit803.5969.91,166.61,321.51,371.7
Gross Margin %54.7857.2560.2160.4259.97
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)451.3564.2676.8802.8843.6
− Exceptional Items (reconciliation)0.10.30.00.00.0
Net Income Adj (tax-effected)376.9461.2541.1649.7678.1
EPS Adj49.6160.1670.5784.3687.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.00
Paid Up Equity Capital15.215.215.215.215.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.